Immunomodulatory effect of anaesthetic technique in breast cancer surgery

Phase 4

• Conditions: breast cancer; partial mastectomy with sentinel lymph node dissection; Cancer - Breast; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12611000301965
• Lead Sponsor: Jie Ae Kim

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

American society of anesthesiologists physical status (ASA) I or II and scheduled for partial mastectomy with sentinel lymph node dissection due to breast cancer

Exclusion Criteria

elevated white blood cell count, eleveted body temperature, elevated c-reactive protein, liver cirrhosis, uncontrolled DM, uncontrolled HT, medication with steroid or non-steroidal anti-inflammatory drug

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
regulatory T cell subset(CD4/CD25/FoxP3) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining[before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation];activated T-cell panel (CD4/CD8/CD69/CTLA4) in peripheral blood will be evaluated using flow cytometry after monoclonal antibody staining[before anaesthetic induction, before discharge from the post anaesthesia care unit (PACU), 24 hour after end of operation]

Secondary Outcome Measures

Name	Time	Method
dose of vaso-active drugs[during operation];pain-scale (0-10 visual analogue scale score)[before discharge from the PACU, 24 hour after end of operation];dose of the pain killer drug[before discharge from the PACU, 24 hour after end of operation];hospital complications including wound problem and elevated temperature will be assessed clinically[from end of operation until discharge]